2022
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV
Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, Aoun-Barakat L, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCohort StudiesCOVID-19COVID-19 TestingEmtricitabineHIV InfectionsHumansLamivudineMaleSARS-CoV-2TenofovirConceptsTDF/FTCTenofovir disoproxil fumarateCoronavirus disease 2019 (COVID-19) outcomesTAF/FTCAntiretroviral therapyTenofovir alafenamideDisoproxil fumarateRisk ratioAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionCOVID-19 ICU admissionsIntensive care unit admissionPrevious COVID-19 diagnosisSyndrome coronavirus 2 infectionCOVID-19-related hospitalizationVeterans Aging Cohort StudySARS-CoV-2 infectionCare unit admissionCoronavirus 2 infectionChronic kidney diseaseHIV viral loadGlomerular filtration rateAging Cohort StudyCorresponding risk ratioPooled logistic regressionAssociations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. The Lancet HIV 2022, 9: e404-e413. PMID: 35659335, PMCID: PMC9647005, DOI: 10.1016/s2352-3018(22)00046-7.Peer-Reviewed Original ResearchConceptsIntegrase strand inhibitorsCause mortalityCohort studyThird drugAntiretroviral drugsMortality rateAntiretroviral Therapy Cohort CollaborationFirst-line ART regimensUK Collaborative HIV CohortART-naive peopleCollaborative HIV CohortAntiretroviral therapy regimensUK Medical Research CouncilMedical Research CouncilCohort CollaborationEfavirenz regimensVirological benefitVirological failureVirological suppressionART regimensHIV cohortHazard ratioRoutine careTherapy regimensUS National Institutes
2019
Improved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals
Tate JP, Sterne JAC, Justice AC. Improved discrimination of mortality with Veterans Aging Cohort Study (VACS) Index 2.0 in HIV-positive individuals. AIDS 2019, Publish Ahead of Print: &na;. PMID: 30649058, PMCID: PMC6749990, DOI: 10.1097/qad.0000000000002140.Peer-Reviewed Original ResearchConceptsWhite blood countC-statisticBlood countVeterans Aging Cohort Study (VACS) IndexAntiretroviral Therapy Cohort CollaborationDiscrimination of mortalityVACS Index 2.0Antiretroviral therapy initiationCD4 cell countHIV-positive populationHarrell's C-statisticHIV-1 RNAHIV-positive individualsKaplan-Meier plotsCohort CollaborationNadir CD4VAC patientsAntiretroviral therapyCause mortalityCD8 ratioTherapy initiationViral suppressionGeneral healthExcess mortalityLaboratory values
2018
Viral suppression among persons in HIV care in the United States during 2009–2013: sampling bias in Medical Monitoring Project surveillance estimates
Bradley H, Althoff KN, Buchacz K, Brooks JT, Gill MJ, Horberg MA, Kitahata MM, Marconi V, Mayer KH, Mayor A, Moore R, Mugavero M, Napravnik S, Paz-Bailey G, Prejean J, Rebeiro PF, Rentsch CT, Shouse RL, Silverberg MJ, Sullivan PS, Thorne JE, Yehia B, Rosenberg ES. Viral suppression among persons in HIV care in the United States during 2009–2013: sampling bias in Medical Monitoring Project surveillance estimates. Annals Of Epidemiology 2018, 31: 3-7. PMID: 30529086, PMCID: PMC6420358, DOI: 10.1016/j.annepidem.2018.11.005.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-HIV AgentsCohort StudiesFemaleHIV InfectionsHumansMaleMiddle AgedPopulation SurveillanceUnited StatesViral LoadConceptsMedical Monitoring ProjectHIV careCare attendanceSurveillance estimatesNorth American AIDS Cohort CollaborationHIV care attendanceMultivariable regression modelsWeighted population estimatesCohort CollaborationVS statusViral suppressionCohort dataNumber of personsConfidence intervalsCareCalendar yearFull calendar yearRegression modelsLast testAttendancePersonsHIVPatientsCareful examination
2016
Cohort Profile: The HIV Atlanta Veterans Affairs Cohort Study (HAVACS)
Guest JL, Moanna A, Wirtz S, Caruth EC, Rentsch C, Marconi VC, Rimland D. Cohort Profile: The HIV Atlanta Veterans Affairs Cohort Study (HAVACS). International Journal Of Epidemiology 2016, 46: 790-791g. PMID: 27272185, DOI: 10.1093/ije/dyw071.Peer-Reviewed Original Research
2013
A Comparison of HAART Outcomes between the US Military HIV Natural History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study (HAVACS)
Guest JL, Weintrob AC, Rimland D, Rentsch C, Bradley WP, Agan BK, Marconi VC, Group I. A Comparison of HAART Outcomes between the US Military HIV Natural History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study (HAVACS). PLOS ONE 2013, 8: e62273. PMID: 23658717, PMCID: PMC3641058, DOI: 10.1371/journal.pone.0062273.Peer-Reviewed Original ResearchConceptsNatural history studiesUS Military HIV Natural History StudyVeterans AffairsCohort studyClinical outcomesHIV treatmentComprehensive HIV treatmentHealthcare systemHistory studiesClinic retentionHAART initiationHAART outcomesCause mortalityAIDS eventsHIV diagnosisSurvival disparitiesStudy cohortDemographic variablesMedication adherenceCrude analysisSurvival ratePatientsSubstance abuseHIVCare